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ABSTRACT 98 
Objectives: To identify genetic determinants of susceptibility to clinical vertebral fractures, 99 
the most common complication of osteoporosis. Methods: Genome-wide association was 100 
carried out in 1,553 postmenopausal women with clinical vertebral fractures and 4,340 101 
controls, with replication in 667 cases and 2,105 controls. Potentially causal variants were 102 
identified using eQTL data from transiliac bone biopsies and bioinformatic studies. Results: 103 
A locus tagged by rs10190845 was identified on chromosome 2q13 which was significantly 104 
associated with clinical vertebral fractures (p=1.27x10
-8
) with a large effect size (odds ratio 105 
1.75, 95% CI 1.4-2.1). Three other suggestive loci were identified on chromosomes 1p31, 106 
11q12 and 15q11. All were novel and had not previously been associated with BMD or 107 
clinical fractures. Analysis of variants that have been associated with spine BMD or fractures 108 
in previous studies identified eight that were significantly associated with clinical vertebral 109 
fractures in this study. Bioinformatic analysis identified several potentially functional SNPs 110 
which were associated with expression of the positional candidate genes TTL and SLC20A1. 111 
Conclusion: We have identified a novel genetic variant with one of the largest effect sizes so 112 
far reported in the field of osteoporosis genetics that is associated with clinical vertebral 113 
fractures by mechanisms that are independent of BMD. Further studies are in now progress to 114 
evaluate the mechanism that underlies this association.  115 
 116 
 117 
 118 
 119 
 120 
 121 
 122 
 123 
 124 
 125 
 126 
 127 
 128 
 129 
 130 
 131 
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INTRODUCTION 132 
Osteoporosis is a common disease with a strong genetic component. It is characterised by low 133 
bone mineral density (BMD), deterioration in the microstructural architecture of bone and an 134 
increased risk of fragility fractures. Vertebral fractures are the most common complication of 135 
osteoporosis [1]. They are characterised by loss of height and deformity of the affected 136 
vertebrae and are associated with an increased risk of other fractures [2]. Vertebral fractures 137 
are commonly overlooked since only 8-30% of patients with radiological evidence of 138 
vertebral fractures come to medical attention [3,4]. About one-third of patients with 139 
radiographic evidence of vertebral fractures also present clinically [5,6] with symptoms such 140 
as back pain, kyphosis and height loss [7].  These patients are said to have clinical vertebral 141 
fractures. Clinical vertebral fractures are associated with a markedly increase risk of future 142 
fractures and increased mortality, indicating their importance as a marker of poor clinical 143 
outcome in osteoporosis [8].  144 
Over recent years, major advances have been made in understanding the genetic 145 
susceptibility to osteoporosis through genome-wide association studies (GWAS) [9-18] and 146 
genome sequencing [19,20]. To date, these studies have identified 62 loci that are associated 147 
with BMD at a genome-wide significant level and 14 loci that are associated with clinical 148 
fractures. In contrast, much less is known about genetic determinants of vertebral fracture. A 149 
previous genome-wide association study published by Oei and colleagues involving a 150 
discovery cohort of 8,717 subjects with morphometric vertebral deformities and 21,793 151 
controls failed to identify any significant genetic predictors of vertebral fracture at a genome-152 
wide significant level [21]. A limitation of this study was the diversity of methods and criteria 153 
used to define the presence of vertebral deformities in different cohorts [21] and the lack of a 154 
consensus on what constitutes a true vertebral fracture on imaging [22]. In view of these 155 
issues, the aim of this study was to perform a genome-wide association study to identify 156 
genetic variants that predisposed to clinical vertebral fractures.  157 
PATIENTS AND METHODS 158 
The study involved a discovery phase involving 1,553 clinical vertebral fracture cases and 159 
4,340 controls and a replication sample of 667 cases and 2,105 controls as summarise in 160 
supplementary Table S1. The genome wide association study was performed using standard 161 
methodology as detailed in the supplementary Text S1.  162 
RESULTS 163 
Characteristics of the study populations 164 
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The mean (± standard deviation) age of the patients with clinical vertebral fractures was 71.3 165 
± 9.3 years with a bone mineral density T-score at the lumbar spine of -2.72 ± 1.4; and at the 166 
femoral neck of -2.57 ± 1.1. The controls  were not matched with the cases by age and did not 167 
undergo phenotyping for vertebral fracture on the basis that clinical vertebral fractures are 168 
uncommon in the general population (estimated incidence of 9.8/1000 person-years in 75-84 169 
year olds) [23]. While it is possible that clinical vertebral fractures may have occurred in 170 
some controls in later life this is unlikely to have substantially affected the results of the 171 
analysis [24]. This approach has been used previously for genome-wide studies in various 172 
common diseases including diabetes, Paget’s disease, and rheumatoid arthritis [25,26]. 173 
Genome-wide association analysis 174 
Since different genotyping platforms were used in the different cohorts (see supplementary 175 
information page 4 for further details), association analysis was conducted following 176 
imputation of all genotypes into the CEU panel of HapMap II reference (see Patients and 177 
Methods section). Following imputation, we analysed 2,366,456 SNPs and identified 31 with 178 
suggestive evidence of association with vertebral fracture (p < 10
-4
). Details are summarised 179 
in supplementary Table 2, and the Manhattan and quantile-quantile plots from the discovery 180 
sample are shown in supplementary Figures 1 and 2. Each study was corrected by genomic 181 
control, and genomic inflation factors ranged between λ = 1.001 to λ = 1.046 for genotyped 182 
SNPs and λ = 1.006 to λ = 1.036 after imputation. 183 
Replication analysis 184 
We analysed the 31 suggestively associated SNPs identified in the discovery cohort 185 
(supplementary Table 2) and seven additional SNPs that had been significantly associated 186 
with clinical fractures in a previous GWAS (supplementary Table 3) [10]. The combined 187 
discovery and replication analysis corrected for age identified one SNP (rs10190845) on 188 
chromosome 2q13 with genome-wide significant evidence of association with clinical 189 
vertebral fractures (p = 1.27x 10
-8
). The predisposing allele had a frequency of 0.034 in cases 190 
compared with 0.022 in controls and the odds ratio for susceptibility to fracture was 1.75 191 
[95% CI: 1.44-2.12] (Figure 1). The results were similar without age correction (p=4.9 x 10
-8
; 192 
odds ratio 1.66 [95% CI: 1.38 – 1.99]). Three other SNPs on chromosomes 1p31, 11q12 and 193 
15q11 were suggestively associated with vertebral fracture (Table 1 and supplementary 194 
Figure 3). None of these regions have previously been found to be associated with BMD or 195 
fracture in other GWAS [10,13] .  196 
The top hit maps to a region which contains eleven potential candidate genes (Figure 2). This 197 
region has previously been implicated as a genetic regulator of bone density by Estrada and 198 
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colleagues [10] who reported that rs17040773 within ANAPC1 was associated with femoral 199 
neck BMD (p = 1.5 x 10
-9
), but not with clinical fractures (p = 0.79). The rs17040773 was not 200 
in linkage disequilibrium with rs10190845 (r
2
=0.006), and, when we performed conditional 201 
analysis on rs17040773, we found that rs10190845 remained significantly associated with 202 
clinical vertebral fractures (p= 2.09 x 10
-8
; odds ratio 1.73 [95% CI: 1.43-2.09]). This 203 
suggests that rs10190845 constitutes an independent signal which predisposes to vertebral 204 
fracture by mechanisms that are independent of an effect on BMD. 205 
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Table 1. Variants showing suggestive or significant association with vertebral fracture  206 
    Discovery (n = 5,893) Replication (n= 2,772) Combined (n= 8,665) 
Chr SNP Position A AF p OR (95% CI) AF p OR (95% CI) p OR (95% CI) I
2
 I
2
 p 
2 rs10190845 112666992 A 0.03 2.4x10-5 1.70 (1.33-2.17) 0.05 1.60x10-4 1.84 (1.34-2.53) 1.27x10-8 1.75 (1.45-2.12) 5.9 0.39 
11 rs7121756 57504473 A 0.29 5.2x10
-5
 1.22 (1.11-1.35) 0.28 0.01102 1.23 (1.05-1.45) 1.27x10
-6
 1.23 (1.13-1.33) 0.0 0.67 
15 rs2290492 90808978 A 0.23 3.4x10-5 1.24 (1.12-1.37) 0.21 0.0214 1.23 (1.03-1.46) 1.61x10-6 1.24 (1.13-1.35) 53.7 0.02 
1 rs1360181 68486723 T 0.84 8.4x10
-5
 0.80 (0.71-0.89) 0.83 0.00831 0.77 (0.64-0.93) 1.87x10
-6
 0.79 (0.71-0.87) 7.7 0.57 
 207 
The allele (A) and allele frequency (AF) for each of the variants is shown along with the p value for association, odds ratio (OR) and 95% 208 
confidence interval (95% CI). The values shown are adjusted for age but similar results were obtained for unadjusted association tests. 209 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
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Functional evaluation of chromosome 2q13 locus 224 
In order to gain insight into the functional basis of the association at 2q13 we used SuRFR 225 
[27] which integrates functional annotation and prior biological knowledge to identify 226 
potentially causal genetic variants. This analysis focused on a linkage disequilibrium block of 227 
approximately 700kb surrounding the top hit rs10190845. We identified a total of 936 SNPs 228 
within the region which were analysed in the GWAS (n=376) or which were in linkage 229 
disequilibrium (r
2
 value of > 0.7) with rs10190845, or which showed suggestive association 230 
to vertebral fractures (p < 5 x 10
-3
). We imputed the genotypes for the SNPs within the region 231 
of interest using the 1000 Genomes phase 3 panel as reference and tested the SNPs for 232 
association with clinical vertebral fractures. We removed 878 of the SNPs since they showed 233 
no association with clinical vertebral fractures in our dataset. The remaining 58 candidate 234 
SNPs were tested for association with the level of expression of genes within the candidate 235 
locus using a bone-derived gene expression dataset (eQTLs) [28] (Tables 2 and 3 and 236 
supplementary Figure 4). This resulted in the identification of nine SNPs which were eQTLs 237 
for genes within the region. These SNPs were analysed by SuRFR along with the top hit 238 
rs10190845 (Table 2 and supplementary Figure 4). 239 
The top ranking variant identified by SuRFR, rs35586251, located within exon 3 of FBLN7 is 240 
a non-synonymous substitution (p.Val119Met). However, analysis using various in silico 241 
software tools yielded inconsistent results with regard to functionality of this SNP at the 242 
protein level (supplementary Table 4). The other SNPs ranked as potentially functional by 243 
SuRFR were associated with expression of TTL, SCL20A or both genes. The top ranking 244 
functional variant rs35586251 was associated with increased expression of TTL (p=6.6 x 10
-
245 
6
). Four other variants were also associated with increased expression of TTL and reduced 246 
expression of SLC20A1 (p-values ranging from 2.1 x 10
-6
 to 10
-5
). The second ranking 247 
variant, rs77172864, in strong LD with the GWAS top hit (r
2
=0.79), was associated with 248 
reduced expression of SLC20A1 (p = 10
-4
) (Tables 2 and 3).  249 
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Table 2. Functionality of SNPs in 2q13 region, predicted by SuRFR 250 
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1 rs35586251 0.17 A (0.02) 2.09x10-4 
1.69 
(1.28-2.24) 
Exon FBLN7 4.47 0 0 7 5 0.02 0 0 9.89 Yes TTL 6.6 x 10-6 
2 rs77172864 0.79 G (0.03) 4.96x10-5 
1.68 
(1.31-2.17) 
Intergenic 0.18 0 0 1 3 0.02 0 0 8.56 Yes SCL20A1 0.0001 
3 rs10190845 1 A (0.03) 2.4x10-5 
1.70 
(1.33-2.17) 
Intergenic 0 0 0 2 3 0.96 0 0 8.06 No - - 
4 rs77996972 0.22 T (0.02) 2.11x10-4 
1.69 
(1.28-2.23) 
Intron FBLN7 1.77 313 0 7 1 0.02 0 0 7.61 Yes 
TTL 
SLC20A1 
3.8 x 10-6 
5.5 x 10
-5
 
5 rs75814334 0.22 T (0.02) 2.11x10-4 
1.69 
(1.28-2.23) 
Intron FBLN7 0.43 239 0 8 1 0.02 0 0 7.56 Yes 
TTL 
SLC20A1 
2.1 x 10-6 
6.6 x 10
-5
 
6 rs74792868 0.22 A (0.02) 2.1x10
-4
 
1.69 
(1.28-2.24) 
Intron FBLN7 0 0 0 9 1 0.02 0 0 7.5 Yes 
TTL 
SLC20A1 
2.0 x 10-5 
2.8 x 10
-5
 
6 rs72943913 0.29 G (0.03) 5.48x10
-5
 
1.67 
(1.30-2.14) 
Intron ZC3H8 0.15 0 0 3 1 0.02 0 0 6.46 Yes SLC20A1 0.0001 
7 rs112275607 0.22 A (0.02) 2.13x10
-4
 
1.69 
(1.28-2.24) 
Intron FBLN7 0 0 0 8 1 0.02 0 0 6.83 Yes 
TTL 
SLC20A1 
2.8 x 10
-6 
6.2 x 10
-5
 
8 rs113085288 0.06 T (0.02) 1.79x10
-4
 
1.70 
(1.29-2.24) 
Intron FBLN7 0 0 0 7 1 0.02 0 0 6.08 Yes SLC20A1 4.1 x10
-6
 
9 rs113428223 0.29 T (0.03) 4.55x10
-5
 
1.70 
(1.31-2.20) 
Intron ZC3H6 0 0 0 2 1 0.02 0 0 5.61 Yes SCL20A1 0.0001 
A (AF): allele (allele frequency); GERP: Genomic evolutionary rate profiling; DNAase HS: DNase hypersensitivity; DNase foot: DNase 251 
footprint; Ernst score: classes of chromatin states (recurrent combinations of chromatin marks); MAF: minor allele frequency; TFBS: 252 
transcription factor binding site.  253 
 254 
 255 
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Table 3.  Correlation between genotypes for potentially functional SNP and bone-specific expression of genes in the candidate region  256 
 257 
RANK SNP GENE PROBE A1 A2 FRQ BETA SE P 
1 rs35586251 TTL 224896_s_at A G 0.017 0.65 0.13 6.62x10
-6
 
2 rs77172864 SLC20A1 230494_at G A 0.013 -0.46 0.11 0.00011 
4 rs77996972 TTL 224896_s_at T C 0.012 0.67 0.13 3.80x10
-6
 
    SLC20A1 230494_at T C 0.012 -0.49 0.11 5.50x10
-5
 
5 rs75814334 TTL 224896_s_at T C 0.013 0.67 0.13 2.10x10
-6
 
    SLC20A1 230494_at T C 0.013 -0.48 0.11 6.60x10
-5
 
6 rs74792868 TTL 224896_s_at A G 0.012 0.66 0.14 2.00x10
-5
 
    SLC20A1 230494_at A G 0.012 -0.53 0.12 2.80x10
-5
 
6 rs72943913 SLC20A1 230494_at G A 0.013 -0.46 0.11 0.00011 
7 rs112275607 TTL 224896_s_at A G 0.013 0.67 0.13 2.80x10
-6
 
    SLC20A1 230494_at A G 0.013 -0.48 0.11 6.02x10
-5
 
8 rs113085288 SLC20A1 230494_at T A 0.008 -0.72 0.14 4.06x10
-6
 
9 rs113428223 SLC20A1 230494_at T C 0.013 -0.46 0.11 0.0001 
 258 
The data shown are only for the associations which were significant after Bonferroni correction (p value for significance <0.0002).  A1: allele 1, 259 
A2: Allele 2, FRQ: frequency of allele 1, BETA: effect size on regression analysis referred to A1 allele, SE: standard error of beta estimate, 260 
probe IDs obtained from the Affymetrix HG U133 2.0 plus array.   261 
 262 
 263 
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Association between clinical vertebral fractures and other osteoporosis related 264 
phenotypes 265 
In order to determine if there was overlap between the SNPs identified as associated with 266 
lumbar spine BMD in previous GWAS with those associated with clinical vertebral fracture 267 
in this study, we evaluated 50 SNPs that have been associated with lumbar spine BMD at a 268 
genome-wide significant level in previous studies in our dataset [10,11,13,19,20]. This 269 
resulted in the identification of four variants that were nominally associated with clinical 270 
vertebral fracture after Bonferroni correction (Table 4). Of the 15 variants previously 271 
associated with clinical fracture [10,13], three were associated with clinical vertebral 272 
fractures in this study. We also analysed the SNPs identified by Nielson and colleagues 273 
(Nielson et al., 2016, unpublished) as genome-wide significant predictors of volumetric 274 
vertebral bone mineral density for association with clinical vertebral fractures in our dataset. 275 
Of the six genome-wide significant SNPs identified in Nielson et al, we found that one was 276 
significantly associated with clinical vertebral fractures after Bonferroni correction 277 
(rs12742784, p=6.24 x 10
-5
).  278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
 287 
 288 
 289 
 290 
 291 
 292 
 293 
 294 
 295 
 296 
 297 
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Table 4. Association between known genetic determinants of spine BMD and clinical vertebral fractures in the combined GWAS 298 
dataset. 299 
Previous studies Present study 
Study SNP locus Candidate gene Phenotype Allele beta p beta p 
Estrada rs1346004 2q24.3 GALANT3 LS-BMD A ‐0.06 3.87x10‐30 +0.16 0.0002 
Estrada rs4727338 7q21.3 SLC25A13 LS-BMD C +0.07 2.13x10‐35 -0.15 0.0004 
Estrada rs6426749 1p36.12 ZBTB40 LS-BMD C +0.1 1.86x10‐44 -0.22 0.0003 
Styrkarsdottir rs7524102 1p36 WNT4 LS-BMD A -0.11 9.2x10
-9
 +0.23 0.0002 
Estrada rs4727338 7q21.3 SLC25A13 Clinical fracture G +0.08 5.9x10-11 +0.14 0.0004 
Estrada rs6426749 1p36.12 ZBTB40 Clinical fracture G +0.07 3.6x10
-6
* +0.22 0.0003 
Estrada rs6959212 7p14.1 STARD3NL Clinical fracture T +0.05 7.2x10-5* +0.15 0.001 
Nielson rs12742784 1p36.12 ZBTB40 Vertebral BMD T +0.09 1.05x10
-10
 -0.20 6.24x10
-5
 
 300 
The variants shown are those that were significant after Bonferroni correction for testing 56 BMD variants (p threshold for association 0.0009) 301 
and 16 fracture variants (p threshold for association 0.003). *SNP significantly associated with clinical fracture after Bonferroni correction (p 302 
threshold at Estrada et al 5x10
-4
). 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
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DISCUSSION 312 
Many advances have been made in defining the genetic determinants of bone mineral density 313 
and fractures through large scale genome-wide association studies, genome sequencing 314 
studies and linkage studies in rare bone diseases [29]. For example, linkage studies have 315 
shown that loss-of-function and gain-of-function variants in LRP5 cause early onset 316 
osteoporosis [30] and high bone mass [31] respectively, whereas loss of function mutations 317 
affecting SOST and LRP4 have been identified as causes of high bone mass and 318 
osteosclerosis [32,33]. Genome-wide association studies and genome sequencing studies 319 
have also been successful in identifying multiple loci that regulate bone mineral density [9-320 
11,19] and a small r number that predispose to clinical fractures [10,19].  321 
Although vertebral fractures are one of the most common and important complications of 322 
osteoporosis, relatively little is known about their genetic basis [34]. In a previous study of 323 
8,717 cases and 21,793 controls, Oei and colleagues failed to identify any locus with 324 
significant evidence of association with morphometric vertebral deformities [21]. In the 325 
present study however, we identified one significant and several suggestive loci that 326 
predisposed to clinical vertebral fractures. Most likely the differences between these studies 327 
are due to the fact that clinical vertebral fractures are a more clearly defined phenotype than 328 
morphometric vertebral deformities [22]. The genome-wide significant SNP identified in the 329 
present study, rs10190845, maps to chromosome 2q13, a region previously associated with 330 
low femoral neck bone density [10]. However, when conditioning on rs17040773, the 331 
previously reported top SNP at the locus [10], the association with rs10190845 remained 332 
significant, indicating that it is a novel signal.  333 
In order to determine if there was an overlap between the results of this study and those 334 
previously reported, we analysed 51 SNPs that have previously been associated with either 335 
spine BMD or clinical fractures and identified seven variants that were significantly 336 
associated with clinical vertebral fracture in this study. The SNPs that were associated with 337 
low BMD in previous studies were associated with an increased risk of clinical vertebral 338 
fractures in this study and those associated with an increased risk of clinical fractures in 339 
previous studies were associated with an increased risk of clinical vertebral fractures in this 340 
study.  341 
Furthermore, when we analysed six SNPs that were significantly associated with vertebral 342 
bone mineral density on quantitative CT analysis (Nielson et al., 2016, unpublished) we 343 
identified one locus on chromosome 1p36, close to ZBTB40, that was significantly associated 344 
with clinical vertebral fracture in this study. These results support the importance of ZBTB40 345 
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as a predictor of clinical fractures and suggest that the mechanism of association is most 346 
probably mediated by changes in BMD. The observations in this study, when taken together 347 
with the findings of Nielson and Estrada [10] indicate that there is a partial overlap between 348 
loci that regulate lumbar spine BMD, and clinical vertebral fractures, but that there are some 349 
genetic determinants of clinical vertebral fracture which are unique and which operate 350 
independently of BMD.  351 
In order to identify the mechanisms by which 2q13 predisposes to vertebral fracture we 352 
conducted functional and bio-informatic studies to determine if rs10190845 or other SNPs 353 
nearby were likely to be functional variants. These studies identified several potentially 354 
functional SNPs in the same LD block as rs10190845, which might account for the 355 
association we observed. The top ranking SNP from SuRFR analysis was rs35586251, which 356 
was strongly associated with expression of the TTL gene within the candidate locus 357 
(supplementary Figure 5). However, the second ranking SNP, rs77172864, was significantly 358 
associated with the expression of SLC20A1. Several other SNPs were also significantly 359 
associated with expression of TTL and/or SLC20A1, raising the possibility that alterations in 360 
expression of one or both genes might account for the predisposition to vertebral fractures.  361 
The TTL gene encodes a tubulin tyrosine ligase involved in regulation of the cytoskeleton. 362 
Previous studies have shown that TTL is involved in neuronal development [35] and injury 363 
signalling [36], raising the possibility that variants that regulate TTL might be involved in 364 
regulating pain perception, which could account for the fact that predisposing variants have 365 
not previously been associated with BMD. Other mechanisms might also be possible and 366 
further studies need to be performed in order to address the role of TTL in vertebral fracture. 367 
The other main candidate gene, SLC20A1, encodes Pit1, which facilitates the entry of 368 
inorganic phosphate  into the cytoplasm [37]. Previous studies have shown that SLC20A1 is 369 
involved in mineralisation [38-41], which raises the possibility that differences in expression 370 
of this gene could be involved in regulating susceptibility for vertebral fractures by an effect 371 
on bone mineralisation. However, SLC20A1 has not been identified previously as a predictor 372 
of BMD or fractures suggesting that an alternative mechanism may be operative, or that TTL 373 
rather than SLC20A1 is the candidate gene within the 2q13 locus.  374 
Limitations of the study include the fact that the total sample size was relatively small and the 375 
power to detect alleles of modest effect size was limited. It’s possible that we may have 376 
missed associations between rare variants and clinical vertebral fractures since the imputation 377 
we performed was against HapMap reference panel. Although case definition was clinically 378 
based there was no significant heterogeneity in the associations we observed across centres.   379 
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A strength of the present study is that it has provided important new information on the 380 
genetic determinants of clinical vertebral fracture. Although clinical vertebral fractures are a 381 
hallmark of osteoporosis, it is of great interest that the top hit and other suggestive hits acted 382 
independently of BMD. This suggests that the variants identified might be acting as markers 383 
for perception of pain or other factors that are associated with the clinical presentation of 384 
vertebral fractures. We also found that some of the variants previously identified as regulators 385 
of spine BMD were associated with clinical vertebral fractures in this study but with effects 386 
that were weaker than the top hit and other suggestive hits. Taken together, the data suggest 387 
that the genetic basis of clinical vertebral fracture is complex involving variants that act 388 
independently of BMD as well as those that are associated with spine BMD. Further research 389 
is now warranted to fully investigate the mechanisms involved.  390 
 391 
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 606 
 607 
 608 
Fig 1. Cohort specific association between rs10190845 and clinical vertebral fracture 609 
The point estimates (squares) and 95% confidence intervals (horizontal lines) for individual 610 
studies are shown with the summary indicated by the diamond using a fixed effect model. 611 
“Italian_replication_1” study corresponds to Florence-InCHIANTI cohorts and 612 
“Italian_replication_2” study comprises the Turin and Siena cohorts. Cohort sizes are 613 
reflected by square dimensions. 614 
 615 
Fig 2. Regional association plot of 2q11 susceptibility locus for clinical vertebral 616 
fracture 617 
The SNPs are colour coded according to the extent of LD with the SNP showing the highest 618 
association signal from the combined analysis (represented as a purple diamond). The 619 
estimated recombination rates (cM/Mb) from HapMap CEU release 22 are shown as light 620 
blue lines, and the blue arrows represent known genes in the region. The red line shows the 621 
threshold for genome-wide significance (p = 5 x 10
-8
). 622 
 623 
 624 
 625 
 626 
 627 
 628 
 629 
 630 
 631 
 632 
 633 
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from the combined analysis (represented as a purple diamond). The estimated recombination rates (cM/Mb) 
from HapMap CEU release 22 are shown as light blue lines, and the blue arrows represent known genes in 
the region. The red line shows the threshold for genome-wide significance (p = 5 x 10-8).  
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PATIENTS AND METHODS 
Phenotype definition 
The case definition of clinical vertebral fractures was that the patient had presented to 
primary or secondary care with symptoms of acute or chronic back pain, height loss, and 
kyphosis, with evidence of vertebral fractures on imaging that were considered to account for 
the symptoms.  Patients with secondary causes of osteoporosis such as premature menopause 
(less than 45-years old), osteogenesis imperfecta, rheumatoid arthritis, inflammatory bowel 
disease, malabsorption, myeloma, thyrotoxicosis, and primary hyperparathyroidism were 
excluded as well as patients who had previously been or were currently being treated with 
corticosteroid therapy (prednisolone > 7.5 mg/day or equivalent for more than 3 months). The 
controls were selected on the basis that they came from the same geographical region as the 
vertebral fracture cases and that DNA samples and/or genome wide association data were 
available. Controls did not undergo phenotyping for the presence of vertebral fractures or 
vertebral deformities under the rationale that clinical vertebral fractures are relatively 
uncommon in the general population and that misclassification of the control group with 
undiagnosed cases is unlikely to influence the results of the analysis substantially, other than 
to have a minor effect on study power. 
Discovery Cohort  
Patients with clinical vertebral fractures included in the discovery cohort (n=1,553) were 
derived from nine centres. Five centres recruited patients from outpatient clinics for the 
treatment of osteoporosis. These were based in Edinburgh, United Kingdom (371); Aarhus, 
Denmark (n=299); Barcelona (n=72) and Santander (n=256), Spain; and Ljubljana, Slovenia 
(n=40). Additional patients with clinical vertebral fractures in the discovery cohort were 
derived from the CAIFOS study (n=98), a randomised trial of calcium supplementation in 
ambulatory women older than 70 years [1]; the Anglo-Australasian Osteoporosis Genetics 
Consortium Australia (AOGC), a population-based, clinic/hospital-based cohort, including 
2073 women from Australia and the United Kingdom (n=234) [2]; the Dubbo Osteoporosis 
Epidemiology Study (DOES), a population-based study including women aged 60 years or 
older, from Dubbo, New South Wales, Australia (n=33) [3]; and the European Prospective 
Investigation of Cancer, Norfolk study (EPIC-Norfolk), a population-based study involving 
over 30,000 people living in Norfolk, UK, aged between 40-79 (n=150) [4].   
Cases and controls were sampled from the same geographical region and same ethnic 
background. Santander and Ljubljana recruited controls locally. The controls for Aarhus 
cases were subjects from Danish National Birth Cohort (DNBC) a population based sample 
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of 100,000 pregnant women from all regions in Denmark [5] . The controls for Spanish cases 
from Barcelona were subjects from Registre Gironi del Cor (REGICOR), a population based 
study of cardiovascular disease in Spain [6]. The controls for cases of British descent from 
Edinburgh, EPIC, AOGC, CAIFOS and DOES were derived from the Wellcome Trust Case 
Control Consortium (WTCCC2) [7] or the 1921 and 1936 Lothian Birth Cohorts [8].  
Replication Cohort 
Clinical vertebral fracture cases for the replication cohort were derived from clinic referrals 
to Edinburgh, United Kingdom (n=236); Florence (n=282), Turin (n=86), Italy; and 
Salamanca, Spain (n=63). Relevant clinical details of the patients from each centre are shown 
in supplementary Table S1.  The controls for the Edinburgh cases were derived from the 
Orkney Complex Disease Study (ORCADES), a cohort study from the Orkney Islands, an 
isolated population in Scotland, UK. The controls for the Italian cases were from the 
Invecchiare nel Chanti (InCHIANTI) cohort, a population-based study of older people from 
the Chianti area in Tuscany, Italy [9]; and the SIENA cohort, a study of postmenopausal 
women recruited from primary care registers of Siena residents and participating in an 
epidemiological survey on risk factors for osteoporosis. Controls were locally recruited for 
the Salamanca samples.  
Ethical Approval 
Written informed consent was obtained from all individuals participating in the studies in the 
various centres and each study received local ethical approval by the relevant ethics 
committee.  
Genotyping and quality control 
A variety of genotyping platforms were used. For the discovery cohorts, the AOGC cases 
were genotyped with a variety of Illumina arrays (arrays including the Illumina Infinium II, 
the Illumina HumHap300; and the 370 CNVDuo and Quad arrays) at the University of 
Queensland Diamantina Institute as previously described [2]. The remainder of the discovery 
cases were genotyped using the Illumina OmniExpress array at the Genetic Laboratory of the 
Erasmus Medical Centre in Rotterdam. For the control cohorts, the DNBC samples were 
genotyped using the Illumina 660w Quad v1.4 array; the REGICOR with an Affymetrix 6.0 
array; the WTCCC2 using an Illumina 1.2M custom array; the Lothian Birth Cohort using the 
Illumina 610 Quad array; the Cantabria, and Slovenia controls using the Illumina 
OmniExpress array.  
Standard quality control measures were performed using PLINK software 
(http://pngu.mgh.harvard.edu/purcell/plink/) [10]; SNPs with low call rate (<95%), those that 
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deviated from Hardy-Weinberg equilibrium (p < 10
-7
), those with minor allele frequency < 
0.01 and missingness χ² p < 10
-7
 were excluded. Samples with low quality (call rate < 97.5%), 
excess heterozygosity, gender mismatch, non-European ancestry and cryptic family 
relatedness were also removed from the final analysis (values deviated more than 4 times the 
standard deviation from the mean). The number of cases and controls after quality control are 
listed in supplementary Table 1. Genotyping cluster plots for significant and suggestive SNPs 
(p < 5 x 10
-5
) were visually inspected and only the SNPs with high quality genotype data 
were used in the analysis. 
Replication genotyping and quality control 
SNPs with p below 10
-4
 in the discovery stage and showing no heterogeneity (I
2
 p > 0.05) 
were selected for replication. Genotyping of replication samples from EDOS, FLOS, 
SALAMANCA, TURIN and SIENA was performed using KASP assays at LGC Ltd 
(Hoddesdon, Herts, UK). ORCADES and InCHIANTI genotyped their samples locally at 
Wellcome Trust Clinical Research Facility, Edinburgh, UK, and Laboratory of 
Neurogenetics, National Institute of Ageing, Bethesda, USA, respectively (using Illumina 
HumanHap 200v2 array and Illumina Infinium I HumanHap 500 Beadchips, respectively). 
Samples with call rates below 90% were removed from the study. Quality control check was 
performed using 45 known genotypes in the replication set, and SNPs with a concordance 
rate > 90% were selected. Hardy-Weinberg Equilibrium was also tested and samples below 
the threshold 10
-7
 were removed. 
Imputation  
Imputation for autosomal SNPs in each case-control cohort was performed using MACH 
software for pre-phasing and MINIMAC for imputation within the BC|SNPmax software (BC 
Platforms Ltd). HapMap European (CEU) phased data from phase II, release 22, genome 
build 36 was used as reference. Association analysis for imputed alleles was performed using 
MACH2QTL as implemented in GRIMP web interphase [11]. Quality control was performed 
after imputation excluding markers with minor allele frequency above 99% and below 1%, 
and SNPs with poor imputation quality (r
2
 < 0.3).  
Association analysis 
During the discovery stage each study was independently tested for association using PLINK 
software [10] (1-degree-of-freedom). Logistic regression models were used to test for 
association using four principal components as covariates. The 38 SNPs selected for 
replication were also tested for association using logistic regression. A similar test was also 
performed using age as covariate.  
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Meta-analysis 
Autosomal SNPs were meta-analysed using fixed-effect, inverse-variance meta-analysis as 
implemented in METAL software [12]. SNPs detected in fewer than 1,000 individuals were 
removed from the analysis. We also set a threshold for standard error < 0.01 and minor allele 
frequency < 0.01. All SNPs below these thresholds were excluded. 
Identification of candidate genes 
Candidate genes were identified after plotting the GWAS results for regional associations 
using LocusZoom software [13]. Recombination areas, defined as genomic regions within 
two recombination peaks, were considered of interest, based on the linkage disequilibrium 
principle. Genes located within these regions were described as candidate genes.  
Expression quantitative trait locus analysis 
The expression of candidate genes in bone tissue was investigated in RNA extracted from 
transiliac bone biopsies derived from 84 Norwegian women as described previously [14]. In 
summary, bone biopsies were obtained from 27 healthy controls, 18 osteopenic and 39 
osteoporotic individuals. Expression profiling was carried out in an Affymetrix HG U133 2.0 
plus array and results were imported into Partek Genomic Suite (Partek Inc., St Louis, MO, 
USA) and normalised using the Robust Multichip Average (RMA) algorithm. Adjustments 
for batch effects and synthesis times were further performed and probe sets with maximal 
log2 signal value below 5 were excluded. Participants of this study were genotyped using an 
Affymetrix 6.0 array and genotypes were imputed using UK10K project and 1000G phase 1 
version 3 phased data as reference panel. Genes that were expressed in bone within the 
recombination area were then tested for association with SNP genotypes by linear regression 
analysis using PLINK software [10] . 
Identification of causal variants 
In order to identify potentially functional variants we focused on a linkage disequilibrium 
block of about 700Kb surrounding the top hit (rs10190845) delimited by a D’ threshold of 0.8 
or greater as using Haploview software [15] (HapMap V2 release 21, CEU population). We 
identified additional proxy SNPs for rs10190845 in the region of interest using SNAP proxy 
(r
2 
> 0.7, 1000 Genomes Pilot 1 reference panel), resulting in a list of 936 variants. Fine 
mapping was performed using 1000 Genomes phase 3 as reference panel, and logistic 
association was carried out in PLINK. 878 out of 936 variants were excluded as they were 
not nominally associated (p > 0.05) with the phenotype of vertebral fracture. The remaining 
58 candidate SNPs were tested for association with genes expressed in bone using RNA 
extracted from transiliac biopsies, as described above. SNPs identified as potential eQTLs, 
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together with the GWAS top hit were evaluated by the R package SuRFR [16]. For the 
purpose of this analysis, the ALL model of SuRFR was selected on the basis that we wanted 
to identify all potentially functional variants regardless of the frequency of the susceptibility 
allele. Exonic variants were analysed in silico using a variety of software: PolyPhen-2, SIFT, 
ESEfinder 3.0, Rescue-ESE 1.0, SNPS3D, EXPASY [17], PANTHER, PSIPRED, and 
Mutation Taster (reviewed in [18]).  
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Supplemental Table 1. Characteristics of the study cohorts.  
 Vertebral fracture cases Controls 
Cohort Number  Age (years) Lumbar Spine T-score Femoral Neck T-score Cohort Number Age 
Discovery        
AROS 299 67.5 + 7.9 -2.9 + 1.2 -3.1 + 1.0 DNBC 1901 29.6 + 4.2 
BARCOS 72 65.6 + 9.6 N/A N/A REGICOR 62 50.8 + 6.9 
CABRIO 256 71.7 + 8.3 -2.6 + 1.2 -2.4 + 1.0 CABRIO-C 263 70.2 + 8.2 
CAIFOS 98 80.5 + 2.8 -1.6 + 1.3 -1.9 + 0.8 WTCCC2 
1298 47.0 + 0.0 
AOGC 234 74.5 + 8.1 -1.8 + 1.8 -2.0 + 1.6 WTCCC2 
DOES 33 81.5 + 7.2 -1.5 + 1.7 -1.8 + 1.1 WTCCC2 
EPIC 150 63.5 + 9.2 N/A N/A WTCCC2 
EDOS 371 72.7 + 8.7 -3.1 + 1.3 -2.6 + 1.0 LBC 784 73.2 + 4.7 
SLOVENIA 40 73.6 + 6.7 N/A N/A SLOVENIA-C 32 61.4 + 5.9 
Total 1553     4340  
        
Replication        
EDOS 236 74.3 + 9.3 -2.9 + 1.4 -2.6 + 0.9 
ORCADES 1101 55.2 + 
13.7 
TURIN 86 74.1 + 8.1 -2.9 + 1.3 -2.5 + 1.0 SIENA 271 63.3 + 6.6 
FLOS 282 61.9 + 9.5 N/A N/A InChianti 670 69.1 + 6.6 
SALAMANC
A 63 73.8 + 8.7 -3.1 + 0.9 -2.6 + 0.9 
SALAMANCA-
C 
63 69.9 + 6.9 
Total 667     2105  
Values are mean ± standard deviation and numbers of individuals. N/A: data not available. 
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Supplemental Table 2. Details of SNPs from discovery sample selected for replication.  
Chr SNP 
Position 
(bp)* 
A AF  OR (95%CI) p 
4 rs7687824 187088056 a 0.30 1.29 (1.18 - 1.42) 8.53x10-8 
11 rs4937421 111845587 g 0.35 0.80 (0.73 – 0.88) 3.69x10
-6
 
2 rs13409720 231255405 a 0.49 0.81 (0.75 - 0.89) 4.14x10-6 
2 rs778356 233492962 t 0.24 1.26 (1.14 - 1.39) 5.15x10-6 
11 rs2473904 34172182 c 0.18 1.29 (1.15 – 1.44) 5.38x10-6 
19 rs2285515 40352290 c 0.38 0.82 (0.75 – 0.89) 1.09x10-5 
2 rs13424896 233465223 t 0.22 0.78 (0.70 - 0.87) 1.28x10
-5
 
6 rs6557164 152044625 t 0.16 1.31 (1.16 - 1.48) 1.49x10
-5
 
4 rs6824581 187004404 t 0.09 1.57 (1.28 - 1.92) 1.57x10
-5
 
1 rs620336 209778831 t 0.02 2.20 (1.53 - 3.16) 1.98x10
-5
 
1 rs12742784 22554953 t 0.20 0.77 (0.69 - 0.87) 2.09x10-5 
2 rs10190845 112666992 a 0.03 1.70 (1.32 - 2.17) 2.36x10-5 
15 rs12591031 81854249 g 0.21 1.27 (1.13 – 1.41) 2.77x10-5 
15 rs12904645 93616356 a 0.21 0.79 (0.71 - 0.88) 3.01x10-5 
15 rs2290492 90808978 a 0.23 1.24 (1.12 - 1.37) 3.45x10
-5
 
1 rs11184882 106715153 c 0.40 0.82 (0.74 – 0.90) 3.46x10
-5
 
2 rs10928585 137484482 a 0.08 1.39 (1.19 - 1.63) 3.71x10
-5
 
6 rs9359760 88650298 t 0.19 1.25 (1.12 - 1.40) 3.94x10
-5
 
1 rs4077413 204845265 c 0.24 0.80 (0.72 – 0.89) 5.1x10-5 
11 rs7121756 57504473 a 0.29 1.22 (1.11 - 1.35) 5.2x10-5 
11 rs4430501 4687303 c 0.34 0.82 (0.75 - 0.90) 5.31x10-5 
11 rs16928809 2893528 a 0.09 0.73 (0.62 - 0.85) 5.5x10-5 
2 rs777346 166244164 t 0.49 1.20 (1.10 - 1.31) 5.68x10
-5
 
13 rs2146819 26895305 t 0.45 1.22 (1.11 - 1.34) 6.27x10
-5
 
16 rs12930710 82816767 t 0.08 1.45 (1.21 - 1.74) 6.45x10
-5
 
3 rs9839600 70118001 g 0.13 0.75 (0.65 – 0.86) 6.56x10
-5
 
3 rs13087574 74928783 a 0.19 0.77 (0.68 - 0.88) 7.53x10-5 
15 rs12903172 59156502 c 0.36 0.83 (0.75 – 0.91) 7.73x10-5 
1 rs1360181 68486723 c 0.16 1.26 (1.12 – 1.41) 8.39x10-5 
6 rs6902885 127422175 t 0.39 1.21 (1.10 - 1.34) 8.61x10-5 
11 rs527199 134268614 c 0.47 0.84 (0.77 – 0.92) 1.00 x 10
-4
 
*HapMap phase II, release 22, genome build 36 was used as reference panel 
The allele (A) and allele frequency (AF) for each of the variants is shown along with the 
p value for association, odds ratio (OR) and 95% confidence interval (95% CI). 
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Supplemental Table 3. Details of SNPs found significantly associated with clinical 
fractures in a previous GWAS [19], also included in the replication stage.  
Chr SNP Position (bp) Allele MAF OR 95%CI P 
18 rs4796995 13698574 g 0.39 1.08 (1.06 - 1.10) 8.80x10
-13
 
7 rs4727338 95958611 g 0.32 1.08 (1.05 - 1.10) 5.90x10
-11
 
10 rs1373004 54097831 t 0.13 1.10 (1.06 - 1.13) 9.00x10
-9
 
11 rs3736228 67957871 t 0.15 1.09 (1.06 - 1.13) 1.40x10
-8
 
4 rs6532023 88992873 t 0.33 1.06 (1.04 - 1.09) 1.70x10
-8
 
2 rs4233949 54513211 c 0.37 1.06 (1.04 - 1.08) 2.60x10
-8
 
3 rs430727 41103568 t 0.47 1.06 (1.03 - 1.08) 2.90x10
-7
 
 
Supplemental Table 4. Bioinformatic analysis of rs35586251 
Software Score Prediction 
Polyphen 0.854 Possibly damaging 
SIFT 0.19 Tolerated 
PANTHER -0.8 (p-value = 0.0998) Neutral 
ESEfinder 3.0  No exonic splicing enhancer binding 
Rescue-ESE 1.0  No binding sequence 
PSIPRED  SNP located with a predicted b-sheet 
SNPS3D -0.17 Damaging 
EXPASY  
Hypothetical protein; no domains 
identified 
Mutation Taster 21 Disease causing 
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Supplemental Figure 1. Loci for susceptibility to clinical vertebral fracture detected by 
genome wide association.  
Manhattan plot of association test results from the discovery stage of the GWAS showing the 
chromosomal position of 2,366,456 genotyped or imputed SNPs plotted against genomic-
control–adjusted −log10 P values The red horizontal line represents the threshold for 
genome-wide significance (p < 5 × 10
-8
) and the blue horizontal line represents the threshold 
for suggestive association (p< 5x10
-6
). 
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Supplemental Figure 2. Quantile- quantile plot in the discovery cohort 
 
The expected negative logP value is shown on the horizontal axis and the observed negative 
logP value on the vertical axis 
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Supplemental Figure 3. Regional association plots for loci suggestively associated with clinical vertebral fractures 
 
 
 
 
 
 
 
 
 
 
 
 
 
The plots shown are for rs1360181 on chromosome 1 (a); rs2290492 on chromosome 15 (b); and rs7121756 on chromosome 11 (c). In each case 
the SNPs are colour coded according to the extent of LD with the SNP showing the highest association signal (represented as a purple diamond). 
The estimated recombination rates (cM/Mb) from HapMap CEU release 22 are shown as light blue lines, and the blue arrows represent known 
genes in the region. 
a b 
d 
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Supplemental Figure 4. Selection of SNPs within 700 kb around rs10190845 to  be ranked by SuRFR software.  
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Supplemental Figure 5. Regional association plots for SNPs representing an eQTL for TTL gene in different tissues. 
 
  
The plots show eQTLs for TTL gene in: a) blood; b) skeletal muscle; c) skin. The SNPs found as eQTLs in the transiliac biopsies were 
highlighted within the red cicle. Blood eQTL SNPs were extracted from the Blood eQTL browser (http://genenetwork.nl/bloodeqtlbrowser/) 
[20]; both, skeletal muscle and skin eQTL SNPs were extracted from The Genome-Tissue Expression Project (GTEx) [21,22]. 
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